The divestiture streamlines Resmed's portfolio but provides no deal value or financial details. Monitor Resmed's Q4 FY2026 regulatory filings for sale price and any gain/loss recognition. The stock may see modest pressure if the sale price implies a small or distressed valuation; absence of price disclosure is a slight negative signal.
Price Chart
Executive Summary
Resmed has agreed to sell its long-term care software business MatrixCare to Frazier Healthcare Partners. The move focuses Resmed on its core sleep, breathing, and home-based healthcare strategy but the press release does not disclose the sale price, implying it may be small relative to Resmed's $31.7B market cap. The transaction is expected to close in Q1 FY2027, subject to regulatory approvals.
Key Facts
- Resmed entered a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners.
- MatrixCare serves over 15,000 providers in skilled nursing, senior living, long-term care, and home health/hospice.
- The transaction is expected to close in Q1 of fiscal year 2027 (approximately October-December 2026).
- The sale price is not disclosed in the press release.
- The divestiture excludes Resmed's other software businesses Brightree (US) and MEDIFOX DAN (Germany).
- Frazier Healthcare Partners is a private equity firm that has raised over $11B and invested in more than 200 healthcare companies.
Financial Impact
Sale price undisclosed; MatrixCare's revenue contribution is not stated, so the financial magnitude relative to Resmed's $31.7B market cap cannot be determined.
Risk Factors
- Undisclosed sale price may be small relative to market cap or imply a discounted valuation.
- Regulatory approvals could delay or block the transaction.
- MatrixCare's departure removes a diversified revenue stream in the long-term care software market.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3323651 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | Insider Cluster | $219.58 $228.42 | ▲ +4.03% | ▲ +4.52% | $218.89 (−0.31%) |
Aug 11, 2026 7w ago | Insider Cluster | $224.84 $219.98 | ▼ −2.16% | ▼ −1.76% | $218.89 (−2.65%) |
Jul 7, 2026 12w ago | Press Release | $205.84 $193.01 | ▼ −6.23% | ▼ −7.10% | $218.89 (+6.34%) |
Jun 1, 2026 17w ago | Press Release | $182.75 $196.94 | ▲ +7.77% | ▲ +10.73% | $218.89 (+19.78%) |
May 19, 2026 19w ago | Press Release | $209.14 $203.22 | ▲ +2.83% | ▲ +4.63% | $218.89 (−4.66%) |
Apr 1, 2026 26w ago | Press Release | $224.09 $228.07 | ▲ +1.78% | ▼ −1.84% | $218.89 (−2.32%) |
Apr 1, 2026 26w ago | Insider Cluster | $222.19 $228.02 | ▲ +2.62% | ▼ −1.14% | $218.89 (−1.48%) |
Apr 1, 2026 26w ago | Insider Cluster | $222.19 $228.02 | ▼ −2.62% | ▲ +1.14% | $218.89 (+1.48%) |
Mar 2, 2026 30w ago | Insider Cluster | $256.94 $252.06 | ▼ −1.90% | ▼ −0.69% | $218.89 (−14.81%) |
Mar 2, 2026 30w ago | Insider Cluster | $256.94 $252.06 | ▼ −1.90% | ▼ −0.69% | $218.89 (−14.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access